Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1991 1
1992 2
1995 1
1998 1
2000 2
2011 1
2019 1
2020 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Unresectable Vulvar Carcinoma"
Page 1
Vulvar carcinoma.
Coleman RL, Santoso JT. Coleman RL, et al. Curr Treat Options Oncol. 2000 Jun;1(2):177-90. doi: 10.1007/s11864-000-0063-4. Curr Treat Options Oncol. 2000. PMID: 12057056 Review.
Carcinoma of the vulva is an uncommon gynecologic malignancy primarily affecting postmenopausal women. ...Patient embarrassment and unfamiliarity and reluctance on the part of the physician to fully evaluate these symptoms add to the delay. Vulvar carcinom …
Carcinoma of the vulva is an uncommon gynecologic malignancy primarily affecting postmenopausal women. ...Patient embarrassmen …
High-dose intensity-modulated chemoradiotherapy in vulvar squamous cell carcinoma: Outcome and toxicity.
Rishi A, Rollins M, Ahmed KA, Hunt DC, Sarkar P, Fernandez DC, Hoffman MS, Apte SM, Shahzad MMK, Chon HS, Chern JY, Wenham RM, Montejo ME. Rishi A, et al. Gynecol Oncol. 2020 Feb;156(2):349-356. doi: 10.1016/j.ygyno.2019.11.027. Epub 2019 Nov 23. Gynecol Oncol. 2020. PMID: 31771865
INTRODUCTION: To evaluate clinical outcomes, pattern of failure, and toxicity after high-dose intensity-modulated radiation therapy (IMRT) for advanced vulvar cancer. ...Tumor doses >66 Gy (p = 0.03) and prior pelvic radiotherapy (p = 0.002) predicted grade 3-4 t …
INTRODUCTION: To evaluate clinical outcomes, pattern of failure, and toxicity after high-dose intensity-modulated radiation therapy ( …
Chemoradiation for advanced primary vulval cancer.
Shylasree TS, Bryant A, Howells RE. Shylasree TS, et al. Cochrane Database Syst Rev. 2011 Apr 13;2011(4):CD003752. doi: 10.1002/14651858.CD003752.pub3. Cochrane Database Syst Rev. 2011. PMID: 21491387 Free PMC article. Review.
SELECTION CRITERIA: Randomised controlled trials (RCTs) or non-randomised studies that included multivariate analyses of chemoradiation in women with locally advanced, primary squamous cell carcinoma of the vulva. ...Adverse events were also reported m …
SELECTION CRITERIA: Randomised controlled trials (RCTs) or non-randomised studies that included multivariate analyses of chemo …
A phase 2 study of combined chemo-immunotherapy with cisplatin-pembrolizumab and radiation for unresectable vulvar squamous cell carcinoma.
Yeku O, Russo AL, Lee H, Spriggs D. Yeku O, et al. J Transl Med. 2020 Sep 14;18(1):350. doi: 10.1186/s12967-020-02523-5. J Transl Med. 2020. PMID: 32928237 Free PMC article. Clinical Trial.
BACKGROUND: Unresectable or metastatic vulvar cancer has relatively poor outcomes despite chemotherapy-sensitized radiation therapy and combination cytotoxic therapy. ...METHODS: We propose a single-arm phase II clinical trial of pembrolizumab combined …
BACKGROUND: Unresectable or metastatic vulvar cancer has relatively poor outcomes despite chemotherapy-sensitized radiation th …
Prolonged continuous infusion cisplatin and 5-fluorouracil with radiation for locally advanced carcinoma of the vulva.
Eifel PJ, Morris M, Burke TW, Levenback C, Gershenson DM. Eifel PJ, et al. Gynecol Oncol. 1995 Oct;59(1):51-6. doi: 10.1006/gyno.1995.1267. Gynecol Oncol. 1995. PMID: 7557615 Review.
Eleven of 12 patients had at least a partial clinical response; one patient had a minimal response of unresectable vulvar disease. ...This is a well-tolerated outpatient regimen that yields a high response rate in patients with massive vulvar carcin …
Eleven of 12 patients had at least a partial clinical response; one patient had a minimal response of unresectable vulvar …
Preoperative chemoradiation for advanced vulvar cancer: a phase II study of the Gynecologic Oncology Group.
Moore DH, Thomas GM, Montana GS, Saxer A, Gallup DG, Olt G. Moore DH, et al. Int J Radiat Oncol Biol Phys. 1998 Aug 1;42(1):79-85. doi: 10.1016/s0360-3016(98)00193-x. Int J Radiat Oncol Biol Phys. 1998. PMID: 9747823 Clinical Trial.
METHODS AND MATERIALS: Seventy-three evaluable patients with clinical Stage III-IV squamous cell vulvar carcinoma were enrolled in this prospective, multi-institutional trial. ...CONCLUSION: Preoperative chemoradiotherapy in advanced squamous cell c …
METHODS AND MATERIALS: Seventy-three evaluable patients with clinical Stage III-IV squamous cell vulvar carcinoma were …
Preoperative chemo-radiation for carcinoma of the vulva with N2/N3 nodes: a gynecologic oncology group study.
Montana GS, Thomas GM, Moore DH, Saxer A, Mangan CE, Lentz SS, Averette HE. Montana GS, et al. Int J Radiat Oncol Biol Phys. 2000 Nov 1;48(4):1007-13. doi: 10.1016/s0360-3016(00)00762-8. Int J Radiat Oncol Biol Phys. 2000. PMID: 11072157 Clinical Trial.
PURPOSE: To determine if patients with carcinoma of the vulva, with N2/N3 lymph nodes, could undergo resection of the lymph nodes and primary tumor following preoperative chemo-radiation. ...CONCLUSION: High resectability and local control rates of the lymph nodes w …
PURPOSE: To determine if patients with carcinoma of the vulva, with N2/N3 lymph nodes, could undergo resection of the lymph no …
Management of locally advanced squamous cell carcinoma of the vulva.
Hoffman MS, Greenberg H, Roberts WS, Fiorica JV, LaPolla JP, Barton DP, Cavanagh D. Hoffman MS, et al. J Gynecol Surg. 1991 Fall;7(3):175-82. doi: 10.1089/gyn.1991.7.175. J Gynecol Surg. 1991. PMID: 10149781 Review.
Carcinoma of the vulva is an uncommon malignancy, accounting for 5% of gynecologic cancers. ...The use of primary radiotherapy for carcinoma of the vulva remains controversial but may be the only option available when the patient has unresectable …
Carcinoma of the vulva is an uncommon malignancy, accounting for 5% of gynecologic cancers. ...The use of primary radiotherapy …
Synchronous radiation and cytotoxic chemotherapy for locally advanced or recurrent squamous cancer of the vulva.
Russell AH, Mesic JB, Scudder SA, Rosenberg PJ, Smith LH, Kinney WK, Townsend DE, Trelford JD, Taylor MH, Zukowski CL, et al. Russell AH, et al. Gynecol Oncol. 1992 Oct;47(1):14-20. doi: 10.1016/0090-8258(92)90068-t. Gynecol Oncol. 1992. PMID: 1427394 Clinical Trial.
Complete clinical response was obtained in 16 of 18 previously untreated patients (89%) and in 4 of 7 patients with recurrent disease following vulvar surgery (57%). ...This experience suggests that initial management with radiation and chemotherapy may offer some p …
Complete clinical response was obtained in 16 of 18 previously untreated patients (89%) and in 4 of 7 patients with recurrent disease …
Cytoreductive combination chemotherapy for regionally advanced unresectable extramammary Paget carcinoma.
Voigt H, Bassermann R, Nathrath W. Voigt H, et al. Cancer. 1992 Aug 1;70(3):704-8. doi: 10.1002/1097-0142(19920801)70:3<704::aid-cncr2820700327>3.0.co;2-5. Cancer. 1992. PMID: 1320453
Extramammary Paget carcinoma (EPC) is considered to originate from the eccrine and apocrine glands of the adnexal skin of the axilla, vulva or penis, scrotum, or perineum. ...
Extramammary Paget carcinoma (EPC) is considered to originate from the eccrine and apocrine glands of the adnexal skin of the axilla, …
11 results